Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis To Take Over Corthera
Novartis is expected to gain exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide, through the acquisition of Corthera. Relaxin is currently in
Novartis is expected to gain exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide, through the acquisition of Corthera. Relaxin is currently in
Ablynx has unveiled results from the open label extension of the phase Ib study of its anti-thrombotic, ALX-0081, in patients with stable angina undergoing percutaneous coronary intervention (PCI).
LifeCycle Pharma (LCP) has submitted the phase 3 protocol for LCP-Tacro in de novo kidney transplant recipients, to the FDA. LCP is expected to review the protocol with
Compugen has signed a collaboration agreement with Pfizer for the predictive discovery by Compugen of therapeutic peptide product candidates, for three drug targets of interest to Pfizer. Reportedly,
Synta Pharmaceuticals (Synta) has initiated phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a
Novexel has signed a definitive agreement whereby the company shall be acquired by AstraZeneca for a total cash consideration of up to $505m. The transaction is expected to
The HHS Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract to Elusys Therapeutics (Elusys) of Pine Brook, for the advanced development of a medication to
Impax Laboratories (Impax) has initiated a challenge of the patents listed by Abbott Laboratories in connection with its Tricor (fenofibrate) tablets, 48mg and 145mg. Tricor is indicated as
Ligand Pharmaceuticals has completed the acquisition of Neurogen following approval of the transaction by Neurogen stockholders. As a result, Ligand gains a fully funded partnership with Merck &
The FDA has approved Sanofi Pasteur’s Fluzone High-Dose, an inactivated influenza virus vaccine for people aged 65 years and older, to prevent disease caused by influenza virus subtypes